StocksMedium•2 November 2026•
1 min read
Teva Discontinues Mid-Stage Neurodegenerative Disorder Clinical Study
Key Facts
1Teva Pharmaceutical Industries announced it will discontinue a mid-stage clinical study for a neurodegenerative disorder treatment.
Teva Pharmaceutical Industries announced it will discontinue a mid-stage clinical study for a neurodegenerative disorder treatment. Reuters reported that the company decided to stop the Phase 2 trial, though specific clinical reasons for the termination were not detailed in the initial report.
TEVA closed at $42.09 on October 30, 2026, having reached a day high of $42.59 and a low of $41.17 during that session. The discontinuation of a mid-stage pipeline candidate represents a negative development for the company's pharmaceutical R&D outlook.